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Abstract
Background: As genes associated with immune-mediated diseases have an increased prior
probability of being associated with other immune-mediated diseases, we tested three such genes,
IL23R, IRF5 and CD40, for an association with type 1 diabetes. In addition, we tested seven genes,
TAF5L, PDCD1, TCF7, IL12B, IL6, ICAM1 and TBX21, with published marginal or inconsistent
evidence of an association with type 1 diabetes.
Methods: We genotyped reported polymorphisms of the ten genes, nonsynonymous SNPs
(nsSNPs) and, for the IL12B and IL6 regions, tag SNPs in up to 7,888 case, 8,858 control and 3,142
parent-child trio samples. In addition, we analysed data from the Wellcome Trust Case Control
Consortium genome-wide association study to determine whether there was any further evidence
of an association in each gene region.
Results: We found some evidence of associations between type 1 diabetes and TAF5L, PDCD1,
TCF7 and IL6 (ORs = 1.05 – 1.13; P = 0.0291 – 4.16 × 10-4). No evidence of an association was
obtained for IL12B, IRF5, IL23R, ICAM1, TBX21 and CD40, although there was some evidence of an
association (OR = 1.10; P = 0.0257) from the genome-wide association study for the ICAM1 region.
Conclusion: We failed to exclude the possibility of some effect in type 1 diabetes for TAF5L,
PDCD1, TCF7, IL6 and ICAM1. Additional studies, of these and other candidate genes, employing
much larger sample sizes and analysis of additional polymorphisms in each gene and its flanking
region will be required to ascertain their contributions to type 1 diabetes susceptibility.
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Type 1 diabetes is a chronic autoimmune disease with a
complex pathogenesis involving multiple genetic and
environmental factors. Before the advent of genome-wide
association (GWA) studies, disease loci were primarily
sought through the testing of candidate genes, selected
based usually upon limited prior information about the
function of the gene and the pathogenic mechanisms of
disease. The candidate gene approach has been successful
in finding disease loci, but as only relatively small num-
bers of genes have been studied, few true positive associa-
tions have been found, despite numerous studies and
enormous effort [1]. Only five type 1 diabetes loci with
compelling evidence had been identified before the
advent of GWA studies: the HLA class II genes on chromo-
some 6p21 [2]; the insulin gene (INS) on 11p15 [3];
CTLA4 on 2q33 [4]; PTPN22 on 1q13 [5,6]; and, IL2RA/
CD25 on 10p15 [7,8]. Another five type 1 diabetes loci
with convincing evidence have so far been identified by
GWA studies in chromosome regions 2q24.3 [9], 12q24,
12q13, 16p13 and 18p11 [10,11].
Previously, we noted that, with the exception of INS [12],
the type 1 diabetes loci contain polymorphisms that have
been associated with susceptibility to other immune-
mediated diseases, such as Graves' disease (GD) and sys-
temic lupus erythemastosus (SLE), suggesting the exist-
ence of shared disease loci [13]. In this study, we tested
three genes, namely, IL23R, IRF5 and CD40, which have
been associated with other immune-mediated diseases
(Table 1), including Crohn's disease (CD), psoriasis, SLE
and GD, for an association with type 1 diabetes. In addi-
tion, we tested seven genes, namely, ICAM1, TAF5L,
PDCD1, TCF7, IL12B, IL6 and TBX21, with marginal or
inconsistent evidence of an association with type 1 diabe-
tes (Table 1). PDCD1 has also been associated with SLE
and Rheumatoid Arthritis (RA). We genotyped reported
polymorphisms, nonsynonymous SNPs (nsSNPs) and tag
SNPs for the IL12B and IL6 regions in up to 7,888 case,
8,858 control and 3,142 parent-child trio samples. In
addition, we used Wellcome Trust Case Control Consor-
tium (WTCCC) [10] GWA study data to determine
whether there was any further evidence of an association
with type 1 diabetes in the linkage disequilibrium (LD)
blocks containing the reported polymorphisms of inter-
est.
Methods
Subjects
Type 1 diabetes families were white European or of white
European descent, with two parents and at least one
affected child comprising DNA samples from up to 918
Finnish multiplex/simplex families [14], 456 multiplex
Diabetes UK Warren I families [15], 278 multiplex
Human Biological Data Interchange (HBDI) families
[16], 80 Yorkshire simplex families, 263 Belfast multi-
plex/simplex [17], 360 Norwegian simplex families [18]
and 240 Romanian simplex families [19]. The single SNPs
from TAF5L and IL12B, two SNPs from PDCD1 and five
SNPs from IL6 were genotyped in all the families. The
TCF7 SNP was genotyped in Warren, Yorkshire, Belfast
and Romanian families. The TBX21 SNP was genotyped in
Warren, Yorkshire, HBDI, Belfast and Romanian families.
The CD40 SNP was genotyped in Warren and HBDI fam-
ilies.
The type 1 diabetes cases (maximum 7,888) [20], the Brit-
ish 1958 Birth Cohort (maximum 8,858) [21] and the UK
Blood Services controls (1,500) have been described pre-
viously [6,10]. All cases and controls are white European.
All DNA samples were collected after approval from the
relevant research ethics committees and written informed
consent was obtained from the participants.
Additional file 1, Table S1 contains a summary of the sam-
ples genotyped for each gene.
SNP identification and genotyping
IL12B is among the genes re-sequenced by the University
of Washington: the Fred Hutchinson Cancer Research
Centre (UW-FHCRC) Variation Discovery Resource [22].
The IL12B SeattleSNPs encompass the introns and exons
between 1.7 kb 5' of exon 2 to 2 kb 3' of the untranslated
exon 8 of IL12B. In this region, they detected 33 polymor-
phisms in their set of 23 DNA samples from Centre
d'Etude du Polymorhisme Humain (CEPH) parents of
European descent. As the untranslated exon 1 and 5'
region beyond it were not sequenced, we-resequenced, a
further 2.9 kb 5', including exon 1 and the known pro-
moter in the same 23 CEPH parents used by SeattleSNPs.
This identified a further four polymorphisms including
the CTCTAA/CG complex promoter deletion insertion
(DIP) (rs17860508), incorrectly described previously as a
4 bp deletion [23].
IL6 was also resequenced by the SeattleSNP Project.
SNPs were genotyped using either Taqman MGB chemis-
try (Applied Biosystems) or Invader Biplex Assay (Third
Wave Technologies, Madison). The D5S2941 microsatel-
lite was genotyped using PCR and evaluated size differ-
ences using an ABI 3700 capillary sequencer.
Wellcome Trust Case Control Consortium
We used data from the WTCCC GWA study [10] to deter-
mine whether there was any evidence of an association
with type 1 diabetes in the LD blocks containing the pol-
ymorphisms of interest. LD blocks were defined using
Haploview [24] and HapMap Project [25] data for the 60
Centre d'Etude du Polymorphisme Humain (CEPH) par-Page 2 of 14
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Table 1: Candidate genes and their previous associations.
Gene and polymorphism Candidacy Previous disease
TAF5L on 1q42
C744A (rs3753886)
TAF5L encodes a protein that is a component of the PCAF 
histone acetylase complex. It may participate in basal 
transcription, serve as a coactivator, function in promoter 
recognition or modify general transcription factors to facilitate 
complex assembly and transcription initiation.
T1D:
▪ Chistiakov et al [35] 247 Russian cases and 258 
(0.52–0.92), P = 0.013.
PDCD1 on 2q37
7146G>A (rs11568821)
872C>T (rs2227981)
Belongs to the B7-CD28 superfamily. These molecules play a 
critical role in the development of the immune response by 
controlling T cell numbers, through a fine balance of stimulation 
and negative regulation, which is essential for the prevention of 
autoimmunity.
SLE, RA and T1D:
▪ Prokunina et al [58] SLE: 7146G>A: 443 families
African-American decent, RR for A allele = 2.6 (1.
A allele = 3.5 (1.4–8.5), P = 9.0 × 10-4 for Mexican
▪ Prokunina et al [37] RA: 7146G>A: 1,175 cases 
(0.99–1.41), P = 0.05.
▪ Lin et al [59] 872C>T: 98 SLE cases and 100 con
allele = 3.32 (1.78–6.21), P < 0.0001, no associatio
▪ Nielsen et al [36] T1D:7146G>A: 192 Danish ca
(1.1–3.3), P = 0.02.
TCF7 on 5q31
Pro19Thr (rs5742913)
Role as a transcription factor in regulating key immune response 
elements and its involvement in T-cell development in the 
thymus.
T1D:
▪ Noble et al [38] 282 USA families, RR = 1.21, PTD
= 1.79, PTDT = 0.007, PESP = 0.03.
To male offspring, PESP = 0.04.
To low HLA risk (non DR3/DR4) offspring, RR =
Early onset offspring, PESP = 0.09.
IL12B on 5q33.3
A1159C (rs3212227)
Microsatellite D5S2941
This gene, encoding the p40 subunit of IL-12, drives the 
differentiation of T lymphocytes into the Th1 subset, which is 
characterized by the production of cytokines that promote cell-
mediated immunity.
T1D:
▪ Morahan et al [49] 249 Eastern Australian multip
P = 0.0025.
235 Australian simplex families, RR for A allele = 
▪ Davoodi-Sermiromi et al [41] 364 USA multiple
= 0.08.
haplotype: allele 2 (D5S2941) and 1159C, P = 0.0
▪ Windsor et al [40] 648 cases and 246 controls –
(1.2–2.0), P = 0.001.
Excess of heterozygotes in cases ≥ 16 yrs diagnos
diagnosis, OR = 2.4 (1.5–3.8), P = 0.0002.
Five studies failed to find an association:
▪ Dahlman et al [60] 2,873 families from UK, USA
▪ McCormack et al [61] 120 cases, 330 controls a
▪ Nistico et al [62] 470 cases and 544 controls fro
▪ Bergholdt et al [63] 337 Danish simplex and 795
▪ Johansson et al [64] from Norway.
IL6 on 7p21
174G>C (rs1800795)
IL6 may contribute to the gradual destruction of the pancreatic 
beta cells, due to its regulatory role in inflammation and the 
immune response.
T1D:
▪ Kristiansen et al [43] 253 Danish families, RR all
Parent-female-trios: RR for C allele = 1.72 (1.25–
Parent-male-trios: RR for C allele = 0.91 (0.67–1.
Age-at-onset males = 14.04 yrs (11.62–16.46) and
model P = 0.002.
▪ Gillespie et al [44] UK 1,230 cases. IL6-174CC le
those diagnosed before, 10 years, P = 0.016.
▪ Jahromi et al [65] 257 cases and 120 newborn co
derived P = 7.8 × 10-5.
53 parent-child trios RR for C allele = 0.83 (0.48–
▪ Eerligh et al [66] 206 Dutch simplex families, no
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ontrols from USA, Spain, Sweden and Argentina, OR 
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from Korea, OR for CC genotype = 1.93 (1.21–3.09), 
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1 ICAM1 on 19p13
G241R (rs1799969)
ICAM-1, upregulated during inflammation and hyperglycemia, is 
involved in the attachment of lymphocytes to the endothelium as 
well as in the priming of effector T cells.
T1D:
Kristiansen et al. [45] 253 Danish families, 
Nejentsev et al [67] 3,695 families from Fin
(0.83–0.99) P = 0.030. 446 families from Ba
Ma et al. [68] 432 cases and 187 controls f
had P-values of 0.026 and <0.001 respectiv
TBX21 on 17q21
His33Gln (rs2240017)
TBX21 has a role in the complex regulation of T lymphocyte 
responses, as a master-regulator of Th1 cytokine IFN-γ gene 
expression.
T1D:
▪ Sasaki et al [46], 153 cases and 200 contr
0.02.
IL23R on 1p31
Arg381Gln (rs11209026)
The protein encoded pairs with the receptor molecule IL12RB1/
IL12Rbeta1, and both are required for IL23A signaling. This 
protein associates constitutively with Janus kinase 2 (JAK2), and 
also binds to transcription activator STAT3 in a ligand-dependent 
manner.
IBD and psoriasis:
▪ Duerr et al [69]
CD: 547 non-Jewish cases and 548 contro
cases and 433 controls, OR = 0.45 (0.27–0
10.
▪ Cargill et al [54] Psoriasis: White North 
(0.50–0.79), P = 1.89 × 10-4.
IRF5 on 7q32.1
-3835 (rs2004640)
Member of a family of transcriptional factors that controls 
inflammatory and immune responses.
SLE:
▪ Sigurdsson et al [70], 679 cases and 438 c
10-7.
▪ Graham et al [71] 1,661 cases and 2,508 c
= 1.47 (1.36–1.60), P = 4.2 × 10-21.
T1D:
One study failed to find an association.
Qu et al [72] 947 T1D families.
CD40 on 20q12
Kozak (rs1883832)
CD40 and CD40L signalling is known to play an important role in 
the immune response. The proteins are expressed in a variety of 
cell types and ligation causes cells to produce inflammatory 
cytokines and cellular adhesion molecules.
GD:
▪ Tomer et al [48] 154 cases and 118 cont
0.048.
▪ Kim et al [73]132 cases and 164 controls 
P = 0.019.
▪ Mukai et al [74] 324 cases and 229 contro
= 0.011)
Two studies failed to find an association:
▪ Houston et al [75] 451 cases and 446 con
▪ Heward et al [76] 800 cases and 785 con
T1D = type 1 diabetes, SLE = systemic lupus erythemastosus, RA = Rheumatoid Arthritis, IBD = Inflammatory Bowel disease, CD = Crohn's disease
Table 1: Candidate genes and their previous associations. (Continued)
BMC Medical Genetics 2007, 8:71 http://www.biomedcentral.com/1471-2350/8/71ents. We used the four gamete rule [26] for defining LD
blocks within Haploview. We note that the 2,000 case and
3,000 (1,500 from the British 1958 Birth Cohort and
1,500 from the UK Blood Services) control samples used
by the WTCCC where also genotyped in this study. We
required WTCCC SNPs to have a minor allele frequency
(MAF) ≥ 0.05, a call rate ≥ 0.99 and no extreme deviation
from Hardy-Weinberg equilibrium (HWE) (χ12 ≤ 25) [27].
Statistical Analysis
All statistical analyses were performed in either Stata [28]
or R [29] statistical systems. Additional routines may be
downloaded [30].
All unaffected parent and control genotypes were assessed
for, and found to be in Hardy-Weinberg equilibrium (P >
0.05). SNPs genotyped in the family collection were ana-
lysed using the transmission/disequilibrium test [31] and,
after estimating pseudo-controls [32], conditional logistic
regression, respectively modelling allelic relative risks
(RRs; a one-degree-of-freedom (df) test) and genotype
RRs (a two-df test). In the case and pseudo-control analy-
sis, we consider the transmitted pair of alleles as the "case"
and the other three possible pairs of transmitted alleles as
"pseudo-controls" in a matched case-control study [32].
The one-df test assumes multiplicative allelic effects and
the two-df test assumes no specific mode of inheritance,
for example, in the analysis of TCF7 C883A, genotype
risks of C/A and A/A were modelled relative to the C/C
genotype.
In the case-control collection, we performed similar tests
using logistic regression models, stratified by 12 broad
geographical regions (Southwestern; Southern; Southeast-
ern; London; Eastern; Wales; Midlands; North Midlands;
Northwestern; East and West Riding; Northern; and, Scot-
land), to allow for geographic variation in allele frequen-
cies across Great Britain [27].
The tag SNPs were selected and analysed using a multilo-
cus test, as previously described [7,33]. Qu et al. [8]
recently reported that the family-based multilocus test
was not confined to heterozygous parents, which compro-
mised the protection against population stratification.
This is incorrect, as described in the studies by Chapman
et al. [33] and Lowe et al. [34], only transmissions from
heterozygous parents contribute to the test.
Results
TAF5L
We genotyped one TAF5L SNP (C744A; rs3753886),
which has previously been associated with type 1 diabetes
[35] (Table 1). We found inconsistent evidence of an asso-
ciation between type 1 diabetes and C744A in the case-
control and family collections. In 7,497 case and 7,496
control genotypes, we obtained marginal evidence of an
association (P = 7.32 × 10-3; OR for allele A = 1.07, 95%
CI 1.02–1.12; Table 2). Although, in 2,645 parent-child
trio genotypes, there was borderline evidence of an asso-
ciation (P = 0.0519), the risk for the minor allele (RR for
allele A = 0.92, 95% CI 0.85–0.99; Table 3) was going in
the opposite direction to that in the case-control collec-
tion.
We found borderline evidence of an association in the
WTCCC, which had two SNPs with a MAF ≥ 0.05 in the 5
kb LD block containing C744A. The lowest P-value was
for C744A (P = 0.0561).
PDCD1
We genotyped two PDCD1 SNPs (7146G>A and 872C>T),
which have previously been associated with type 1 diabe-
tes [36] and RA respectively [37] (Table 1). We found
inconsistent evidence of an association between type 1
diabetes and 7146G>A in the case-control and family col-
lections (Tables 2 and 3). In 7,888 case and 8,858 control
genotypes, we obtained limited evidence of an association
(P = 0.0102; OR for allele A = 1.10, 95% CI = 1.02–1.17).
In 3,125 parent-child trio genotypes, no evidence of an
association was found (P = 0.498). For the second SNP,
872C>T, no evidence of an association was found in
either collection (Tables 2 and 3).
There were no WTCCC SNPs with a MAF ≥ 0.05 in the 12
kb LD block containing 7146G>A. We note that 7146G>A
was not included in either HapMap or the WTCCC study.
TCF7
We genotyped one TCF7 SNP (C883A; rs5742913), which
had previously been associated with type 1 diabetes [38]
(Table 1). Despite obtaining no evidence of an overall
association, Noble et al. [38] proceeded to analyse sub-
groups, defined by up to three criteria, in which they
found an excess of the A allele transmitted: from fathers;
to male offspring; to low HLA risk (non-DR3/DR4) off-
spring; and, to early onset offspring (Table 1). We found
some evidence of an association between type 1 diabetes
and C883A in the case-control and family collections
(Tables 2 and 3). In 7,434 case and 8,637 control geno-
types, in contrast to Noble et al. [38], we obtained evi-
dence of an association with type 1 diabetes (P = 4.16 ×
10-4; OR for allele A = 1.13, 95% CI = 1.06–1.22). In 1,556
parent-child trio genotypes, no evidence of an association
was found (P = 0.608). In addition, we found no evidence
of an association between type 1 diabetes and C883A
when comparable subgroup analyses, as described by
Noble et al. [38], were performed (see Additional file 1,
Table S2). We also performed, a case-only regression anal-
ysis of cases and affected offspring from the case-control
and family collections respectively, which showed no con-Page 5 of 14
(page number not for citation purposes)
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Genotypes
CA AA
3,803 (50.7) 1,867 (24.9)
3,815 (50.9) 1,753 (23.4)
05 (0.97–1.14) 1.14 (1.04–1.25)
0.0244
GA AA
1,574 (20.0) 118 (1.5)
1,670 (18.9) 100 (1.1)
08 (1.00–1.17) 1.32 (1.00–1.74)
0.0268
CT TT
2,787 (48.4) 1,015 (17.6)
3,518 (48.3) 1,310 (18.0)
00 (0.92–1.08) 0.97 (0.87–1.07)
0.760
CA AA
1,604 (21.6) 121 (1.6)
1,703 (19.7) 108 (1.3)
13 (1.04–1.22) 1.32 (1.01–1.73)
1.91 × 10-3
AC CC
1,402 (32.5) 171 (4.0)
1,488 (31.6) 173 (3.7)
06 (0.96–1.16) 1.13 (0.90–1.42)
0.324
GC CC
4,312 (48.7) 1,612 (18.2)
3,814 (49.0) 1,515 (19.5)
04 (0.97–1.12) 1.11 (1.01–1.21)
0.0879B
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Table 2: Association analyses in type 1 diabetes cases and controls.
Alleles
TAF5L C744A (rs3753886) C A CC
7,497 cases 7,457 (49.7) 7,537 (50.3) 1,827 (24.4)
7,496 controls 7,671 (51.2) 7,321 (48.8) 1,928 (25.7)
OR (95% CI) 1.00 (reference) 1.07 (1.02–1.12) 1.00 (reference) 1.
P 7.32 × 10-3
PDCD1 7146G>A (rs11568821) G A GG
7,888 cases 13,966 (88.3) 1,810 (11.7) 6,196 (78.6)
8,858 controls 15,846 (88.5) 1,870 (11.5) 7,088 (80.0)
OR (95% CI) 1.00 (reference) 1.10 (1.02–1.17) 1.00 (reference) 1.
P 0.0102
PDCD1 872C>T (rs2227981) C T CC
5,758 cases 6,699 (58.2) 4,817 (41.8) 1,956 (34.0)
7,289 controls 8,440 (57.9) 6,138 (42.1) 2,461 (33.8)
OR (95% CI) 1.00 (reference) 1.00 (0.95–1.06) 1.00 (reference) 1.
P 0.586
TCF7 Pro19Thr (rs5742913) C A CC
7,434 cases 13,022 (87.6) 1,846 (12.4) 5,709 (76.8)
8,637 controls 15,355 (88.9) 1,919 (11.1) 6,826 (79.0)
OR (95% CI) 1.00 (reference) 1.13 (1.06–1.22) 1.00 (reference) 1.
P 4.16 × 10-4
IL12B A1159C (rs3212227) A C AA
4,321 cases 6,898 (79.8) 1,744 (20.2) 2,748 (63.6)
4,711 controls 7,588 (80.5) 1,834 (19.5) 3,050 (64.7)
OR (95% CI) 1.00 (reference) 1.06 (0.98–1.14) 1.00 (reference) 1.
P 0.134
IL6 174G>C (rs1800795) G C GG
7,785 cases 8,726 (56.0) 6,844 (44.0) 2,928 (33.1)
8,852 controls 10,168 (57.4) 7,536 (42.6) 2,456 (31.6)
OR (95% CI) 1.00 (reference) 1.05 (1.01–1.10) 1.00 (reference) 1.
P 0.0291
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0.179
CG GG
224 (5.2) 2 (0.1)
227 (4.7) 3 (0.1)
1.08 (0.88–1.31) 1.10 (0.16–7.54)
0.759
GA AA
727 (11.9) 17 (0.3)
778 (12.3) 26 (0.4)
0.95 (0.85–1.06) 0.67 (0.36–1.26)
0.285
TG GG
2,860 (50.6) 1,310 (23.2)
2,998 (49.6) 1,465 (24.2)
1.03 (0.94–1.12) 0.96 (0.86–1.06)
0.353
CT TT
1,624 (37.0) 268 (6.1)
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ICAM1 G241R (rs1799969) G A GG
5,776 cases 10,257 (88.8) 1,295 (11.2) 4,553 (78.8)
6,094 controls 10,787 (88.5) 1,401 (11.5) 4,787 (78.6)
OR (95% CI) 1.00 (reference) 0.96 (0.89–1.05) 1.00 (reference)
P 0.382
TBX21 His33Gln (rs2240017) C G CC
4,342 cases 8,456 (97.4) 228 (2.6) 4,116 (94.8)
4,763 controls 9,293 (97.6) 233 (2.4) 4,533 (95.2)
OR (95% CI) 1.00 (reference) 1.08 (0.89–1.30) 1.00 (reference)
P 0.459
IL23R Arg381Gln (rs11209026) G A GG
6,087 cases 11,413 (93.7) 761 (6.3) 5,343 (87.8)
6,303 controls 11,776 (93.4) 830 (6.6) 5,499 (87.2)
OR (95% CI) 1.00 (reference) 0.93 (0.84–1.03) 1.00 (reference)
P 0.183
IRF5 -3835 (rs2004640) T G TT
5,657 cases 5,834 (51.6) 5,480 (48.4) 1,487 (26.3)
6,044 controls 6,160 (51.0) 5,928 (49.0) 1,581 (26.2)
OR (95% CI) 1.00 (reference) 0.98 (0.93–1.03) 1.00 (reference)
P 0.451
CD40 Kozak (rs1883832) C T CC
4,392 cases 6,624 (75.4) 2,160 (24.6) 2,500 (56.9)
4,702 controls 7,132 (75.8) 2,272 (24.2) 2,680 (57.0)
OR (95% CI) 1.00 (reference) 1.03 (0.96–1.10) 1.00 (reference)
P 0.456
OR = odds ratio for the minor allele, 95% CI = 95% confidence interval.
Table 2: Association analyses in type 1 diabetes cases and controls. (Continued)
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C883A. Similarly, a case-only gene-gene interaction anal-
ysis between C883A and the known type 1 diabetes loci,
HLA, INS, CTLA4 and PTPN22, revealed no consistent evi-
dence of an interaction with C883A (see Additional file 1,
Table S3). We note that the lack of evidence for an inter-
action between C883A and PTPN22 1858C>T contradicts
a previous study reporting an over-transmission of
PTPN22 1858T to individuals who have at least one copy
of TCF7 883A (P = 0.015) [39].
We found no evidence of an association in the WTCCC,
which had two SNPs with a MAF ≥ 0.05 in the 66 kb LD
block containing C883A. The SNP with the lowest P-value
was rs756699 (P = 0.694). We note that C883A was not
included in either HapMap or the WTCCC study.
IL12B
IL12B has been reported to be associated with type 1 dia-
betes in some but not all studies (Table 1). Therefore, we
investigated the contribution of IL12B to type 1 diabetes
susceptibility, as thoroughly as possible, by genotyping a
SNP (A1159C; rs3212227), two rare nsSNPs (rs3213096
and rs3213119), a microsatellite (D5S2941) and a set of
tag SNPs for the IL12B region. In 4,321 case, 4,711 control
and 3,015 parent-child genotypes, we obtained no evi-
dence of an association between type 1 diabetes and
A1159C (P = 0.134 and 0.630 respectively; Tables 2 and
3). In addition, we performed a case-only analysis to rep-
licate the association reported by Windsor et al. [40]
between A1159C and age-at-diagnosis (Table 1). How-
ever, no evidence of an age-at-diagnosis effect at A1159C
was found (see Additional file 1, Table S4).
The microsatellite D5S2941, in IL12B intron 2, had previ-
ously been reported to be associated with type 1 diabetes
by Davoodi-Semiromi et al. [41] (P < 0.006; Table 1).
They detected two alleles, a major allele 1 with eight
repeat units and a minor allele 2 with nine repeat units,
and found over-transmission of allele 2 to affected off-
spring. We detected an additional two, extremely rare,
alleles: allele 3 (ten repeat units) and allele 4 (seven repeat
units), both found at frequency of <0.001. In 1,327 case
and 1,160 control genotypes, we obtained no evidence of
an association between type 1 diabetes and D5S2941
allele 2 (P = 0.114). Davoodi-Semiromi et al. also reported
an association between type 1 diabetes and the D5S2941
allele 2-1159C haplotype (P = 0.02) and suggested the
possibility that the causal variant remained ungenotyped
and elsewhere in IL12B [41]. Consequently, we also ana-
lysed this haplotype using an EM algorithm-based routine
to assign haplotypes to cases and controls, which were
then analysed using a linear model weighted by the poste-
rior haplotype probabilities for each case or control. Again
we found no association with disease for this haplotype in
1,298 case and 1,111 control genotypes (P = 0.195).
To investigate the possibility of a polymorphism associ-
ated with type 1 diabetes in IL12B that we, or others, have
not yet genotyped, we adopted an linkage disequilibrium
(LD) mapping approach using tag SNPs (Table 4). We
combined resequencing data in 23 CEPH parents from the
SeattleSNP project [22] with inhouse resequencing of the
untranslated exon 1 and 5', not resequenced in the Seat-
tleSNP project (Methods). In the combined resequencing
data, we identified 38 polymorphisms, comprising 34
SNPs (four SNPs provided by the in house resequencing),
three deletion-insertion polymorphisms (DIPs) and the
microsatellite D5S2941 (see Additional file 1, Table S5).
Six tag SNPs were selected (minimum R2 = 0.80) from 25
SNPs with a minor allele frequency (MAF) ≥ 0.10. The set
of tag SNPs was genotyped in the case-control collection
and analysed using a multilocus test, which tests for an
association between type 1 diabetes and the tag SNPs due
Table 3: Association analyses in type 1 diabetes families.
Transmission/disequilibrium test
Parent-child-trios 
(families)
Parental MAF Minor allele RR (95% CI) P
Transmitted Untransmitted
TAF5L A1159C (rs3212227) 2,645 (2,515) 46.8 1,299 1,400 0.92 (0.85–0.99) 0.0519
PDCD1 7146G>A (rs11568821) 3,125 (2,742) 9.3 516 538 0.96 (0.85–1.08) 0.498
PDCD1 872C>T (rs2227981) 2,190 (1,831) 42.5 1,111 1,043 1.07 (0.98–1.16) 0.143
TCF7 C883A (rs5742913) 1,556 (1,224) 11.2 327 314 1.04 (0.89–1.21) 0.608
IL12B A1159C (rs3212227) 3,015 (2,606) 18.9 949 933 1.02 (0.93–1.12) 0.712
IL6 174G>C (rs1800795) 2,803 (2,651) 47.0 1,411 1,360 1.04 (0.97–1.12) 0.333
TBX21 His33Gln (rs2240017) 1,989 (1,374) 2.7 111 100 1.11 (0.85–1.45) 0.449
CD40 Kozak (rs1883832) 1,446 (795) 24.1 522 542 0.96 (0.85–1.08) 0.540
MAF = minor allele frequency, RR = relative risk for minor allele, 95% CI = 95% confidence interval.Page 8 of 14
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cus test P-value was 0.940, providing no evidence of an
association between type 1 diabetes and the IL12B region
(Table 4). We note that rs17860508, the promoter DIP
CTCTAA/CG, was selected as a tag SNP. Previously, this
polymorphism had been associated with asthma suscepti-
bility [23] and IgE levels [42], but we found no associa-
tion with type 1 diabetes (4,367 case and 4,714 control
genotypes, P = 0.878).
Finally, we tested for an association between type 1 diabe-
tes and two rare nsSNPs (rs3213096 and rs3213119).
Although the MAF was 0.022 for both nsSNPs in the Seat-
tleSNPs CEPH sequencing panel, in the case-control col-
lection, rs321096 had a much lower MAF of 0.0035 in
controls and consequently, we had no power in a collec-
tion of 4,383 case and 4,732 control genotypes to test for
an association. The other nsSNP, rs3213199, with MAF of
0.034 in controls, showed no evidence of an association
with type 1 diabetes in 4,348 case and 4,691 control gen-
otypes (P = 0.0941).
We found limited evidence of an association in the
WTCCC, which had six SNPs with a MAF ≥ 0.05 in the 14
kb LD block containing A1159C. The only associated SNP
was rs6859018 (P = 0.0274), which is in perfect LD (r2 =
1) with A1159C in 60 CEPH parents. Consequently,
based on the perfect LD between rs6859018 and A1159C,
we can conclude that this association is a false positive.
We note that A1159C was not included in the WTCCC
study.
IL6
As IL6 has been reported to be associated with type 1 dia-
betes [43] (Table 1), we sought to replicate this associa-
tion by genotyping IL6-174G>C (rs1800795) and a set of
tag SNPs for the IL6 region. We found inconsistent evi-
dence of an association between type 1 diabetes and IL6-
174G>C in the case-control and family collections (Tables
2 and 3). In 7,785 case and 8,852 control genotypes, we
obtained limited evidence of an association with type 1
diabetes (P = 0.0291; OR for allele C = 1.05, 95% CI =
1.01–1.10). In 2,803 parent-child trio genotypes, no evi-
dence of an association was found (P = 0.333). As Kris-
tiansen et al. [43] found evidence that the IL6-174C allele
was only associated with type 1 diabetes in female off-
spring (Table 1), we analysed IL6-174G>C by sex. In the
cases and controls, we obtained limited evidence of an
association in males (P = 0.0378), but not in females (see
Additional file 1, Table S6a) and in the families, we found
no evidence of an association in either male or female
type 1 diabetes offspring (see Additional file 1, Table
S6b).
Previously, Gillespie et al. [44] found frequency differ-
ences in IL6-174G>C genotypes between males and
females diagnosed ages > 10 years. Consequently, we con-
ducted a similar case-only analysis using a multinomial
logistic regression model to adjust for broad geographical
region within Great Britain and for population of the
cases and affected offspring, respectively. We found no
evidence of genotype differences between 5,700 male and
5,292 female cases and affected offspring (P = 0.370) and
when analysed by age-at-diagnosis (see Additional file 1,
Table S7).
To test for an association between type 1 diabetes and the
IL6 region, we adopted a LD mapping approach. We used
SeattleSNP resequencing data in 23 CEPH parents, four
tag SNPs were selected (minimum R2 = 0.80) from twelve
SNPs with a MAF ≥ 0.10 (see Additional file 1, Table S8).
We found no evidence for association in the case-control
collection (multilocus test P = 0.236). However, in the
family collection, limited evidence of an association was
found (multilocus test P = 0.0231) (Table 4).
We found no evidence of an association in the WTCCC,
which had two SNPs with a MAF ≥ 0.05 in the 4 kb LD
block containing IL6-174G>C. The SNP with the lowest P-
value was rs2069835 (P = 0.343). We note that IL6-
174G>C was included in the WTCCC study, but was
dropped as the call rate was below 0.99.
Table 4: Tag SNP results for IL6 and IL12B regions.
Multilocus test P-values
Exons Sequencing source Polyorphisms Tag SNPs Families Cases and controls
IL12B 8 Seattle SNPs and in house 
(23 subjects)
33 (from Seattle)
4 (in house)
25 had a MAF ≥ 0.10
6 N/A 0.940
1,590 cases and 1,748 
controls
IL6 6 Seattle SNPs (23 subjects) 49
12 had MAF ≥ 0.10
4 0.0231
3,320 parent-child 
trios
0.236
3,486 cases and 3,783 
controls
We selected tag SNPs from SNPs with a MAF ≥ 0.10. MAF = minor allele frequency.Page 9 of 14
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We genotyped one ICAM1 SNP (G241R; rs1799969),
which has previously been associated with type 1 diabetes
[45] (Table 1). However, no evidence of an association
was found in 5,776 cases and 6,094 controls (P = 0.382;
Table 2).
We found some evidence of an association in the WTCCC,
which had two SNPs with a MAF ≥ 0.05 in the 15 kb LD
block containing G241R. The most associated SNP was
rs892188 (P = 0.0257; OR for allele T = 1.10, 95% CI =
1.01–1.19), located just over 2 kb upstream of the 3' UTR
of ICAM5, which has low LD (r2 = 0.274) with G241R. We
note that G241R was not included in the WTCCC study.
TBX21
We genotyped one TBX21 SNP (His33Gln; rs2240017),
which had previously been associated with type 1 diabetes
in a Japanese case and control collection [46] (Table 1).
No evidence for association in either collection was found
(Tables 2 and 3). We note that the G (Gln) allele fre-
quency in controls was 0.024 (Table 2) and in parents
0.027, considerably lower than reported in Japanese by
Sasaki et al. (MAF = 0.105) [46], but similar to that found
in other European populations (MAF = 0.030) [47].
We found no evidence of an association in the WTCCC,
which had one SNP with a MAF ≥ 0.05 in the 14 kb LD
block containing His33Gln. The SNP, rs2240017, had a P-
value of 0.131. We note that His33Gln was not included
in the WTCCC study.
IL23R
We genotyped one IL23R SNP (Arg381Gln; rs11209026),
which has previously been associated with IBD and pso-
riasis (Table 1). In 6,087 cases and 6,303 controls, we
found no evidence of an association with type 1 diabetes
(P = 0.183; Table 2).
The only WTCCC SNP with a MAF ≥ 0.05 in a 15 kb LD
block containing Arg381Gln was Arg381Gln (P = 0.857).
IRF5 and CD40
We genotyped two SNPs from IRF5 and CD40 (-3835/
rs2004640 and 168A>G/rs1883832, respectively), which
have previously been associated with SLE and GD respec-
tively (Table 1). The CD40 -168A>G SNP has been
reported to disrupt the Kozak consensus sequence neces-
sary for efficient translation [48]. No evidence of an asso-
ciation was found for either SNP (Tables 2 and 3).
We found no evidence of an association in the WTCCC,
which had no SNPs with a MAF ≥ 0.05 in the 5 kb LD
block containing -3835 and 168A>G was not contained
within a block. Neither -3835 nor 168A>G were included
in the WTCCC study.
Discussion
In this study, we have tested ten candidate genes for an
association with type 1 diabetes using large case-control
and family collections. We did obtain some evidence,
albeit inconsistent between collections, of an association
with TAF5L (C744A), PDCD1 (7146G>A), TCF7 (C883A)
and IL6 (IL6-174G>C, rs2069849 and the IL6 region).
Although TAF5L (C744A; rs3753886), PDCD1
(7146G>A; rs11568821), TCF7 (C883A; rs5742913) and
IL6 (IL6-174G>C; rs1800795) have previously been asso-
ciated with type 1 diabetes, the possibility remains that
these associations are false positives. However, the find-
ings reported here maybe the result of the case-control
collection having more power than the family collection
to detect SNPs with relatively small effects in type 1 diabe-
tes or being in weak LD with the causal locus. Conse-
quently, additional studies will be required to ascertain
the contribution of TAF5L, PDCD1, TCF7 and IL6 to type
1 diabetes susceptibility. The case-control collection
(8,000 cases and 8,000 controls) provided about 60%
power to detect an OR of 1.2 for a MAF of 0.10 at a P-value
of about 1 × 10-6; and about 96% power for a MAF of 0.20.
The family collection (3,125 parent-child trios) provided
less power to detect an OR of 1.2, after increasing the P-
value to 1 × 10-3, there was about 45.1 % power for a MAF
of 0.10 and about 81.4% power for a MAF of 0.20.
We did not obtain any evidence of an association between
type 1 diabetes and either ICAM1, IL12B or TBX21, all of
which had previously been associated with type 1 diabetes
[45,46,49]. However, limited evidence of an association
with rs892188, located in the LD block containing the
reported SNP in ICAM1, was provided by the WTCCC.
Additional studies will be required to ascertain the contri-
bution of rs892188 to type 1 diabetes susceptibility. The
previous reports of disease associations may well have
been false positives, which have to be expected given: the
low prior probability, even for candidate genes [1,50], of
detecting a true causal locus of complex disease; the fre-
quent use of relatively small sample sizes and of nominal
levels of significance; and, the large numbers of SNPs
tested for an association with type 1 diabetes. It is interest-
ing to note that when, by chance, a true positive result is
found, as in the case for PTPN22 Arg620Trp SNP in type 1
diabetes [5], it is replicated by many groups, very rapidly
[6,39,51,52], although this has a large effect approaching
an OR = 2.
Finally, we did not obtain any evidence of an association
between type 1 diabetes and IL23R, IRF5 or CD40, all of
which have previously been associated with other
immune-mediated diseases including, most recently,Page 10 of 14
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Lack of association of IL23R, IRF5 and CD40 with type 1
diabetes helps to delineate pathogenic mechanisms
between type 1 diabetes and other immune-mediated dis-
eases, especially when the associations reported for the
other diseases are highly likely to be true positive results.
Nevertheless, for these and other loci, it is possible that
one or more of these genes could have allelic heterogene-
ity in which one allele predisposes to certain autoimmune
diseases and a second allele at a different location in the
gene predisposes to another. This possibility necessitates
the continued investigation of further polymorphisms
within each gene.
Conclusion
The functional candidate gene approach has now been
superseded by GWA studies, which are detecting major
susceptibility loci [10,11,53,55]. Most of the confirmed
loci from GWA studies have ORs ≤ 1.3, consistent with an
L-shaped distribution of allelic effect sizes (that is, a small
number of genes with large effects and a large number of
genes with small effects) [1,11]. TAF5L, PDCD1, TCF7, IL6
and ICAM1 may be amongst the numerous loci with small
effects in type 1 diabetes. We note that genes found with
small effects on disease may have much larger effects in
subgroups of phenotypically defined cases. For example,
CTLA4 genotypes has a small effect overall in type 1 dia-
betes (OR = 1.20, 95% CI 1.13–1.27), but subclassifica-
tion of cases with or without the thyroid peroxidase
autoantibodies revealed an increased effect (OR = 1.49,
95% CI 1.29–1.72) for cases with autoantibodies (with-
out autoantibodies OR = 1.16, 95% CI 1.10–1.24) [56].
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